Furthermore, depletion of CD4+ and CD8+ T cells significantly reversed the effect of cetuximab+IL-1α-NP (Fig. 6) suggesting that IL-1α in combination with cetuximab can induce a T cell-dependent anti-tumor immune response. Here, CD8A is linked to neoplasm.